Cardiovascular Systems Inc (CSII)

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATRO, BLL, CCE, CSII, EGN, EMR, HCI, IMPV, K, MANT, MLCO, MX, OI, RDS.A, RDS.B, TPRE, USCR, WMC Downgrades: CCO, CLF, GCAP, INCY, KMPR, OMCL, OMI, SHEN, SWIR, UEPS Initiations: ORMP Read on to get TheStreet Quant Ratings' detailed report:

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) today announced that the U.

Cardiovascular Systems, Inc. (NASDAQ: CSII): Conference Call Scheduled for Today, May 3, 2017, at 3:45 PM CT (4:45 PM ET) Revenues of $52.

In recent trading, shares of Cardiovascular Systems, Inc have crossed above the average analyst 12-month target price of $30.50, changing hands for $30.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

PAD is the biggest disease that most people have never heard about.

PAD is the biggest disease that most people have never heard about.

PAD is the biggest disease that most people have never heard about.

PAD is the biggest disease that most people have never heard about.

Cardiovascular Systems' saline infusion pump is being recalled.

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) today announced it has initiated a voluntary recall of its 7-10014 Saline Infusion Pump.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of its fiscal 2017 third-quarter conference call on Wednesday, May 3, 2017, at 3:45 p.

Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Diamondback 360 Coronary OAS Micro Crown as a frontline treatment for de novo severely...

Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) announced that the United States Food and Drug Administration (FDA) has approved the Diamondback 360 ® Coronary OAS Micro Crown system to facilitate stent delivery in...

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), in partnership with Cardiovascular Research Foundation (CRF), announces the first subject enrolled in its ECLIPSE clinical trial.

Investors eyeing a purchase of Cardiovascular Systems, Inc shares, but cautious about paying the going market price of $26.64/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $22.50 strike, which has a bid at the time of this writing of $1.55.

Cardiovascular Systems (CSI) (NASDAQ: CSII) today announced the addition of independent board member Martha Goldberg Aronson, an experienced business executive with deep healthcare and medical industry experience.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today released 1-year results from its Coronary Orbital Atherectomy System Study (COAST) in a late-breaking presentation at the 2017 Cardiovascular Research Technologies...

On Thursday, February 16, 2017, Cardiovascular Systems' (NASDAQ: CSII) Chairman, President and Chief Executive Officer, Scott Ward, and Chief Financial Officer, Larry Betterley, will present at the LEERINK Partners 6 th...

Cardiovascular Systems (CSI) (NASDAQ: CSII) presented six-month data from its LIBERTY 360° post-market study in a presentation at the 29th International Symposium on Endovascular Therapy (ISET) in Hollywood, Florida.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial...

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of its fiscal 2017 second-quarter conference call on Wednesday, January 25, 2017, at 3:45 p.

Investors eyeing a purchase of Cardiovascular Systems, Inc stock, but cautious about paying the going market price of $23.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $17.50 strike, which has a bid at the time of this writing of 95 cents.

Investors eyeing a purchase of Cardiovascular Systems, Inc stock, but cautious about paying the going market price of $23.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $17.50 strike, which has a bid at the time of this writing of 95 cents.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) has signed an exclusive distribution agreement with Medikit Co.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today debuted the design of its new ECLIPSE clinical trial in a presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial...